Literature DB >> 16140761

Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity.

Katharina Skrabal1, Sentob Saragosti, Jean-Louis Labernardière, Francis Barin, François Clavel, Fabrizio Mammano.   

Abstract

Individuals infected with human immunodeficiency virus type 1 (HIV-1) harbor a mixture of viral variants with different sequences and in some instances with different phenotypic properties. Major and rapid fluctuations in the proportion of viral variants coexisting in an infected individual can be observed under strong pharmacological and immune selective pressure. Because of the short half-life of HIV-infected cells and of HIV virions in the blood, plasma virus populations are highly relevant to HIV evolution in the face of these selective pressures. Here we analyzed the sensitivity to antibody-mediated neutralization of viral variants coexisting in the plasma virus populations of two infected patients. For each patient, several replication-competent viral clones were constructed that carry primary envelope gene sequences obtained from a single plasma sample. Viral clones differed in their tropism and replicative capacity and in the number and positions of glycosylation sites in the envelope glycoproteins. Viruses were tested against heterologous and autologous sera obtained at different time points. Interestingly, we found that viral variants coexisting in each plasma sample were highly heterogeneous in terms of sensitivity to neutralization. The order of sensitivity depended on the serum used and was not associated with virus tropism. The neutralization potency of sera increased with the duration of the infection for both autologous and heterologous neutralization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140761      PMCID: PMC1212602          DOI: 10.1128/JVI.79.18.11848-11857.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

Authors:  P Poignard; R Sabbe; G R Picchio; M Wang; R J Gulizia; H Katinger; P W Parren; D E Mosier; D R Burton
Journal:  Immunity       Date:  1999-04       Impact factor: 31.745

Review 2.  The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

Authors:  P W Parren; J P Moore; D R Burton; Q J Sattentau
Journal:  AIDS       Date:  1999       Impact factor: 4.177

3.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

4.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

5.  Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.

Authors:  B Chackerian; L M Rudensey; J Overbaugh
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.

Authors:  P Borrow; H Lewicki; X Wei; M S Horwitz; N Peffer; H Meyers; J A Nelson; J E Gairin; B H Hahn; M B Oldstone; G M Shaw
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

Review 7.  A vaccine for HIV type 1: the antibody perspective.

Authors:  D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

8.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

Authors:  A K Pilgrim; G Pantaleo; O J Cohen; L M Fink; J Y Zhou; J T Zhou; D P Bolognesi; A S Fauci; D C Montefiori
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

10.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

View more
  8 in total

1.  Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant.

Authors:  Xueling Wu; Adam B Parast; Barbra A Richardson; Ruth Nduati; Grace John-Stewart; Dorothy Mbori-Ngacha; Stephanie M J Rainwater; Julie Overbaugh
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy.

Authors:  Justin R Bailey; Kara G Lassen; Hung-Chih Yang; Thomas C Quinn; Stuart C Ray; Joel N Blankson; Robert F Siliciano
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

4.  Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5X4 HIV type 1 in brain and other tissues.

Authors:  Megan E Mefford; Paul R Gorry; Kevin Kunstman; Steven M Wolinsky; Dana Gabuzda
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

5.  Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers.

Authors:  Olivier Lambotte; Guido Ferrari; Christiane Moog; Nicole L Yates; Hua-Xin Liao; Robert J Parks; Charles B Hicks; Kouros Owzar; Georgia D Tomaras; David C Montefiori; Barton F Haynes; Jean-François Delfraissy
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

6.  Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response.

Authors:  Katherine A Bosch; Stephanie Rainwater; Walter Jaoko; Julie Overbaugh
Journal:  Virology       Date:  2010-01-19       Impact factor: 3.616

7.  Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

Authors:  Thushan I de Silva; Marlén Aasa-Chapman; Matthew Cotten; Stéphane Hué; James Robinson; Frederic Bibollet-Ruche; Ramu Sarge-Njie; Neil Berry; Assan Jaye; Peter Aaby; Hilton Whittle; Sarah Rowland-Jones; Robin Weiss
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

8.  Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses.

Authors:  Tamara Nora; Francine Bouchonnet; Béatrice Labrosse; Charlotte Charpentier; Fabrizio Mammano; François Clavel; Allan J Hance
Journal:  Retrovirology       Date:  2008-02-29       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.